Physician profile
Mark A Humphrey
NPI 1831126648
$4,006.87
in general payments reported to CMS, 2019-2025
30 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $175 · 2022: $47.16 · 2023: $824 · 2024: $1,182 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.22 | 2019-2025 | |
| Pfizer INC. | $629.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $347.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $339.59 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $229.64 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $184.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $172.66 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $162.03 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $141.99 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $119.18 | 2022-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.91 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.44 | 2019-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $98.00 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $96.69 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.68 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $74.13 | 2025 | Gemtesa |
| Abbott Laboratories | $61.04 | 2023-2025 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $54.61 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $50.37 | 2023-2024 | Auvelity |
| Allergan, INC. | $41.96 | 2019 | |
| Amarin Pharma, INC. | $29.66 | 2019 | |
| Corium, LLC | $27.50 | 2025 | Azstarys |
| Corcept Therapeutics | $23.94 | 2025 | Korlym |
| Vertex Pharmaceuticals Incorporated | $23.40 | 2025 | |
| Lundbeck LLC | $21.75 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $20.90 | 2025 | |
| Dexcom, INC. | $17.59 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $13.38 | 2020 | |
| Horizon Therapeutics Plc | $12.71 | 2019 | |
| Shire North American Group INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Humphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.